Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Buyout/​LBO
  • Financing Rounds
  • 1

Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) General Information

Description

An injection drug for women's healthcare and pain relief. The Duraclon (clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management while Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • One Riverfront Place
  • Newport, KY 41071
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line)‘s full profile, request access.

Request a free trial

Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line)‘s full profile, request access.

Request a free trial